Extrakorporale Therapie bei Sepsis – wann steht das therapeutische Fenster offen?

Zusammenfassung

Die Sepsis ist eine der häufigsten Indikationen für die Intensivtherapie. Die überschießende pathologische Immunreaktion des Patienten und die daraus resultierenden Organdysfunktionen mit hoher Mortalität sind die zentralen pathophysiologischen Komponenten der Sepsis, die früh im Krankheitsverlauf initiiert werden. Die wenigsten septischen Patienten sterben an der Infektion per se, sondern an ihrer systemisch ablaufenden inflammatorischen Antwort auf die Pathogene und Endotoxine der Infektion mit der ausgelösten Freisetzung von Zytokinen. Der adjuvante Einsatz extrakorporaler Verfahren zur raschen Entfernung übermäßig erhöhter Toxine und Entzündungsmediatoren aus dem Blut, stellt einen pathophysiologisch plausiblen Therapieansatz dar. In den letzten Jahren bestätigten Studien das Potenzial verschiedener Methoden der extrakorporalen Blutreinigung bei Sepsis und septischem Schock. Weitere Forschungsanstrengungen sind erforderlich, um die optimalen Anwendungsstrategien zu definieren und den klinischen Nutzen robust nachzuweisen. Die Zukunft liegt in der personalisierten Nutzung dieser Technologien.

Publication History

Article published online:
04 September 2025

• Literatur

• 1 Gründling M. Sepsis - Beispiel für eine verbesserte Behandlungsqualität. Deutsches Ärzteblatt 2023; 120: A1594-A1595
• 2 Evans L, Rhodes A, Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. Intensive Care Med 2021; 47: 1181-1247
• 3 Hillebrand U, Rex N, Seeliger B. et al. Was ist gesichert in der Therapie der Sepsis? Ein Update. Innere Medizin 2024; 65: 1199-1208
• 4 Stahl K, Seeliger B, David S. et al. Was ist gesichert in der Therapie der Sepsis?. Internist 2020; 61: 1238-1248
• 5 Bottari G, Ranieri VM, Ince C. et al. Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives. Critical Care 2024; 28: 432
• 6 Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383: 2255-2273
• 7 Jarczak D, Kluge S, Nierhaus A. Septic hyperinflammation – Is there a role for extracorporeal blood purification techniques?. Int J Mol Sci 2024; 25: 3120
• 8 Amornphimoltham P, Yuen PST, Star RA. et al. Gut leakage of fungalderived inflammatory mediators: part of a gutliverkidney axis in bacterial sepsis. Dig Dis Sci 2019; 64: 2416-2428
• 9 Alpkvist H, Ziegler I, Mölling P. et al. Damage-associated molecular patterns in bacteraemic infection, including a comparative analysis with bacterial DNA, a pathogen-associated molecular pattern. Scientific Rep 2024; 14: 23499
• 10 David S, Bode C, Stahl K. et al. EXCHANGE2: investigating the efficacy of addon plasma exchange as an adjunctive strategy against septic shock – a study protocol for a randomized, prospective, multicenter, openlabel, controlled, parallelgroup trial. Trials 2023; 24: 277
• 11 Gruda MC, Ruggeberg KG, O’Sullivan P. et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads. PLoS One 2018; 13: e0191676
• 12 Jansen A, Waalders NJB, van Lier DPT. et al. CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Crit Care 2023; 27: 117
• 13 Nierhaus A, Morales J, Wendt D. et al. Comparison of the CytoSorb 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study. Minim Invasive Ther Allied Technol 2022; 31: 1058-1065
• 14 Rey S, Kulabukhov VM, Popov A. et al. Hemoperfusion using the LPS-selective mesoporous polymeric adsorbent in septic shock: a multicenter randomized clinical trial. Shock 2023; 59: 846-854
• 15 Bottari G, Buccione E, Bayrakci B. et al. Extracorporeal blood purification in European pediatric intensive care units – a consensus statement. JAMA Network Open 2025; 8: e2457657
• 16 Brouwer WP, Duran S, Kuijper M. et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care 2019; 23: 317
• 17 Rugg C, Klose R, Hornung R. et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective “genetic” matched analysis. Biomedicines 2020; 8: 539
• 18 Chen JJ, Lai PC, Lee TH. et al. Blood purification for adult patients with severe infection or sepsis/septic shock: a network meta-analysis of randomized controlled trials. Crit Care Med 2023; 51: 1777-1789
• 19 Pappalardo F, Cardinale A, D’Ettore N. et al. Blood purification in critically ill patients: not enough, but still helpful. Crit Care 2023; 27: 357
• 20 Putzu A, Schorer R, Lopez-Delgado JC. et al. Blood purification and mortality in sepsis and septic shock: a systematic review and meta-analysis of randomized trials. Anesthesiology 2019; 131: 580-593
• 21 Dellinger RP, Bagshaw SM, Antonelli M. et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. J Am Med Assoc 2018; 320: 1455-1463
• 22 Rachoin JS, Foster D, Giese R. et al. Importance of endotoxin clearance in endotoxemic septic shock: an analysis from the evaluating use of Polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemic septic shock (EUPHRATES) trial. Crit Care Expl 2020; 2: e0083
• 23 Zarbock A, Nadim MK, Pickkers P. et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol 2023; 19: 401-417
• 24 Schultz P, Schwier E, Eickmeyer C. et al. High-dose Cyto-Sorb hemoadsorption is associated with improved survival in patients with septic shock: a retrospective cohort study. J Crit Care 2021; 64: 184-192
• 25 Kogelmann K, Hubner T, Schwameis F. et al. First evaluation of a new dynamic scoring system intended to support prescription of adjuvant CytoSorb hemoadsorption therapy in patients with septic shock. J Clin Med 2021; 10: 2939
• 26 Becker S, Lang H, Vollmer Barbosa C. et al. Efficacy of CytoSorb: a systematic review and meta-analysis. Crit Care 2023; 27: 215
• 27 Klinkmann G, Koball S, Reuter D. et al. Hemoperfusion with Cytosorb: Current knowledge on patient selection, timing and dosing. Adsorption: The New Frontier in Extracorporeal Blood Purification. Ronco C, Bellome R. Contrib Nephrol 2023; 200: 17-24
• 28 Dennler U, Glas M, Brunkhorst F. et al. Kodierleitfaden Sepsis 3.0. Deutsches Qualitätsbündnis Sepsis und Deutsche Sepsis Gesellschaft. Accessed May 13, 2025 at: https://www.sepsis-gesellschaft.de/sepsisdefinition-und-kodierung/
• 29 Schetter V, Bernhardt W, DeGroot K. et al. Standard der Therapeutischen Apherese 2023 der Deutschen Gesellschaft für Nephrologie e. V. Accessed May 13, 2025 at: https://www.dgfn.eu/nachrichtenleser-184/standard-der-therapeutischen-apherese-2023.html
• 30 Armstrong A, Tang Y, Mukherjee N. et al. Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes. Front Immunol 2024; 15: 1448201
• 31 Ronco C, Chawla L, Husain-Syed F. et al. Rationale for sequential extracorporeal therapy (SET) in sepsis. Crit Care 2023; 27: 50
• 32 Bellomo R, Ankawi G, Bagshaw S. et al. Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup. Nephrol Dial Transplant 2024; 39: 1945-1964
• 33 Supady A, Brodie D, Wengenmayer T. Extracorporeal haemoadsorption: does the evidence support its routine use in critical care?. Lancet Respir Med 2022; 10: 307-312